| abstract |
The present disclosure describes (i) a MET inhibitor that is INC280, or a pharmaceutically acceptable salt or hydrate thereof, and (ii) which are jointly active in the treatment of proliferative diseases, and (ii) It relates to pharmaceutical products comprising combinations of EGFR inhibitors, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments. |